From Skincare Staple to Cancer-Fear Controversy: How CeraVe Became the Face of Benzene- Cancer Debate

Nearly two years after U.S.-based independent testing laboratory Valisure raised concerns about benzoyl peroxide (BPO)-based acne treatments, CeraVe remains at the center of online debates, lawsuits and consumer anxiety, particularly among younger skincare users in India who have increasingly encountered viral social-media posts linking acne products to cancer-related concerns.

The issue has gained fresh momentum recently after a wave of Instagram Reels, TikTok videos, X posts and skincare-influencers' content reignited fears surrounding benzoyl peroxide-based acne products. Several widely shared posts warned consumers about possible links between these acne treatments and benzene, a chemical classified as a known human carcinogen, prompting confusion and intense debate across online skincare communities.

As videos accumulated millions of views and users questioned whether they should discontinue popular acne products, CeraVe emerged as one of the most frequently discussed brands in the controversy. The online debate has fueled renewed scrutiny of the brand's acne-treatment portfolio and brought back years-old regulatory issue firmly in the public spotlight.

How the Benzene Controversy Began?

The roots of the controversy stretch back to 2021, when independent laboratory Valisure reported detecting benzene contamination in several sunscreen and after-sun products sold in the United States. The findings triggered recalls and heightened regulatory attention toward contamination risks in consumer healthcare products.

The issue escalated significantly in March 2024 when Valisure submitted a citizen petition to the U.S. Food and Drug Administration (USFDA), alleging that acne treatments containing benzoyl peroxide could generate benzene as the ingredient degrades over time. Unlike earlier contamination cases where benzene was believed to enter products through manufacturing or raw materials, Valisure argued that the chemical could be formed within the product itself under certain unfavourable storage conditions.

The laboratory claimed that some tested products generated benzene levels above the FDA's conditional limit of 2 parts per million, sparking widespread concern because benzoyl peroxide is among the most commonly used acne-treatment ingredients worldwide.

How the Controversy Reached India

While the controversy originated in the United States, it found a new audience in India through social media.

Skincare influencers, dermatology content creators and consumer-health accounts began sharing videos discussing benzene, product recalls and lawsuits linked to acne treatments. In many cases, CeraVe became the focal point of discussions because of its popularity among Indian consumers and strong presence on e-commerce platforms.

Several viral posts blurred distinctions between products specifically recalled by manufacturers and products merely mentioned in lawsuits or discussions surrounding benzoyl peroxide. As a result, many consumers were left uncertain about which products were actually affected.

Indian dermatologists and skincare professionals subsequently entered the debate, attempting to separate established regulatory findings from social-media speculation and urging consumers to rely on evidence-based guidance rather than viral content.

Lawsuits Put CeraVe Under the Spotlight

The controversy has also moved beyond laboratories and into courtrooms.

Following Valisure's findings, multiple lawsuits were filed in the United States against manufacturers of benzoyl peroxide acne products, including products sold under the CeraVe brand. Several complaints alleged that consumers were not adequately informed about potential benzene-formation risks and argued that purchasers may have made different buying decisions had they known about the concerns raised by independent testing.

Legal databases and court filings indicate that at least six federal lawsuits were filed involving acne-treatment products linked to the benzene controversy. While the cases remain ongoing and no court has concluded that CeraVe products cause cancer, the litigation significantly amplified public attention and transformed a scientific debate into a mainstream consumer issue.

Recall at Sister Brand Fuels Fresh Questions

Public scrutiny intensified further in 2025 when L'Oréal voluntarily recalled all lots of La Roche-Posay Effaclar Duo in the United States following concerns related to benzene contamination.

Although the recalled product belonged to La Roche-Posay rather than CeraVe, both brands operate under the L'Oréal umbrella. The recall reignited questions about benzoyl peroxide-based acne products and triggered renewed discussions across social media regarding the safety of similar formulations sold by major skincare companies.

Around the same time, the USFDA conducted its own review of benzoyl peroxide acne treatments and announced voluntary recalls involving certain products from multiple manufacturers. However, CeraVe products were not included in those recalls.

Why CeraVe Remains Linked to the Issue?

Despite the absence of a CeraVe-specific USFDA recall, the brand continues to be closely associated with the benzene controversy because of a combination of factors: Valisure's widely publicized findings, ongoing lawsuits, the brand's own legacy, the recall of a sister brand's acne product, repeated social-media discussions and continuing consumer concerns about long-term product safety.

For CeraVe, the challenge has increasingly become reputational as much as regulatory. What started as a technical discussion about ingredient stability has evolved into a broader debate about transparency, product safety and consumer trust.

As lawsuits continue through U.S. courts and social-media discussions periodically resurface, CeraVe remains one of the most visible faces of a controversy that shows little sign of disappearing from public conversation.